Blog & Analysis #phispers #pharmaflow

This week, Phispers brings you news on US President Donald Trump’s new payment model, proposed ahead of the midterm polls, to closely align the cost of Medicare Part B drugs with the prices in other countries. The USFDA ap...

As compared to the previous months, September was a slower month for dealmaking. The Wall Street Journal recently attributed the drought in big biotech deals to the riskiness of the business. In a note to clients, a Jefferies he...

This week, Phispers brings you news on AstraZeneca’s Lynparza that has shown strong benefits for women with ovarian cancer. Novartis has expanded its radioligand therapeutic (RLT) pipeline of targeted oncology treatment by...

This week, Phispers brings you news from Dr. Reddy’s Laboratories in India which is divesting its API plant in Hyderabad in order to optimize its cost structure. J&J and Bayer’s blood thinner Xarelto was found to...

The big news from the world of pharmaceuticals this week came from two cancer researchers — James P. Allison of the US and Tasuku Honio of Japan — who bagged the Nobel Prize in Physiology or Medicine for unleashing the...

In case you thought the US Food and Drug Administration (FDA) and EU’s actions against China’s Zhejiang Huahai Pharmaceutical (ZHP) for supplying commonly used blood pressure medicine valsartan with cancer-causi...

This week, Phispers brings you new twists to the valsartan impurities saga. First, the FDA posted its observations at Zhejiang Huahai Pharmaceuticals, post a recent inspection of its Linhai (China) site.  Second, the EMA sa...

This week, Phispers brings you the latest on the valsartan contamination. FDA and EMA have found the presence of an additional unexpected impurity in valsartan drug products. We also bring you the string of measures being undertak...

In August, the biotech boom of 2018 continued unabated and the Wall Street Journal reported that investment banks have lured top biotech analysts with guaranteed pay packages of US$ 3 million or more. At this time of the yea...

This week, Phispers has news on Indian generic drug makers. First, Sun Pharma and Dr. Reddy’s Laboratories announced their reworked strategies that are driven by severe pressures in the US market. While DRL plans to double i...